Boston Scientific Corporation
BSX
$100.64
$1.721.73%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.75B | 15.91B | 15.23B | 14.71B | 14.24B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.75B | 15.91B | 15.23B | 14.71B | 14.24B |
| Cost of Revenue | 5.29B | 4.97B | 4.77B | 4.56B | 4.39B |
| Gross Profit | 11.46B | 10.94B | 10.46B | 10.15B | 9.85B |
| SG&A Expenses | 5.98B | 5.75B | 5.43B | 5.34B | 5.19B |
| Depreciation & Amortization | 857.00M | 840.00M | 843.00M | 840.00M | 829.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.75B | 13.08B | 12.51B | 12.18B | 11.83B |
| Operating Income | 3.00B | 2.83B | 2.72B | 2.53B | 2.42B |
| Income Before Tax | 2.28B | 2.20B | 2.14B | 2.15B | 1.99B |
| Income Tax Expenses | 436.00M | 414.00M | 319.00M | 377.00M | 393.00M |
| Earnings from Continuing Operations | 1.85K | 1.79K | 1.82K | 1.77K | 1.59K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 7.00M | 4.00M | 4.00M | 2.00M | 1.00M |
| Net Income | 1.85B | 1.79B | 1.83B | 1.77B | 1.59B |
| EBIT | 3.00B | 2.83B | 2.72B | 2.53B | 2.42B |
| EBITDA | 4.27B | 4.06B | 3.95B | 3.74B | 3.61B |
| EPS Basic | 1.26 | 1.22 | 1.25 | 1.21 | 1.08 |
| Normalized Basic EPS | 1.18 | 1.10 | 1.05 | 0.96 | 0.91 |
| EPS Diluted | 1.25 | 1.21 | 1.23 | 1.19 | 1.07 |
| Normalized Diluted EPS | 1.16 | 1.09 | 1.04 | 0.95 | 0.91 |
| Average Basic Shares Outstanding | 5.89B | 5.88B | 5.87B | 5.84B | 5.81B |
| Average Diluted Shares Outstanding | 5.94B | 5.93B | 5.92B | 5.89B | 5.85B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | 0.00% | 0.00% | 0.79% | 1.76% |